The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons

Abstract

ESKD; Dialysis; Kidney transplantation; Patient survival

Enfermedad renal terminal; Diálisis; Trasplante de riñón; Supervivencia del paciente

Malaltia Renal Crònica Terminal (MRCT); Diàlisi; Trasplantament de ronyó; Supervivència del pacient

The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper summarizes the ERA Registry Annual Report 2022, with a special focus on comparisons by sex. The supplement of this paper contains the complete ERA Registry Annual Report 2022. Data was collected from 53 national and regional KRT registries from 35 countries. Using this data, incidence, and prevalence of KRT, kidney transplantation rates, survival probabilities, and expected remaining lifetimes were calculated. In 2022, 530 million people of the European general population were covered by the ERA Registry. The incidence of KRT was 152 per million population (pmp). In incident patients, 54% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes mellitus (22%). At KRT initiation, 83% of patients received haemodialysis, 12% received peritoneal dialysis, and 5% underwent pre-emptive kidney transplantation. On 31 December 2022, the prevalence of KRT was 1074 pmp. In prevalent patients, 48% were 65 years or older, 62% were male, the most common PRD was of miscellaneous origin (18%), 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. In 2022, the kidney transplantation rate was 40 pmp, with most kidneys coming from deceased donors (66%). For patients starting KRT between 2013 to 2017, 5-year survival probability was 52%. Compared with the general population, the expected remaining lifetime was 66% and 68% shorter for males and females, respectively, receiving dialysis, and 46% and 49% shorter for males and females, respectively, living with a functioning graft.

The ERA Registry is funded by the European Renal Association (ERA). This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. N.M. reports being board member for the NICE guidelines and Cyprus Renal Association. M.M.V. reports receiving grants from Instituto de Salud Carlos; consulting fees, payment for lectures, support for attending meetings and/or travel from Novo-Nordisk, Astra Zeneca, Boherinheim, Ingelheim-Lilly, Bayer, Menarini, Vifor; and is president of the Nephrology Madrilenian Society. A.M.D.S. ´ reports being board member for the Voivodeship Consultant for Nephrology. M.F.S.R. reports receiving consulting fees from Fresenius, Baxter, Nipro; payment for lectures from Baxter, Fresenius, Physidia; and support for attending meetings and/or travel from Vifor, Fresenius, NovoNordisk; and is board member of Fresenius European Home Dialysis Advisory Board and the Direction Committee of the Spanish Society of Nephrology. M.O.V. reports receiving consulting fees of SANOFI and support for attending meetings and/or travel by Fressenius and Sandoz. A.Å. reports receiving grants from Oripharm and AstraZeneca; payments from Oripharm and Glenmark; and receipt of study drug from AstraZeneca. I.R. reports being president of the Czech Society of Nephrology and Secretary-Treasurer of ERA 2017- 2024. M.O.R. reports payment for lectures from AstraZeneca; and is board member of AstraZeneca, ISN Eastern & Central Europe Regional Board, Ministry of Social Affairs of Estonia, and Nordic Peritoneal Dialysis Council. A.O. has received grants from Sanofi; is director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes; has received consultancy or speaker fees or travel support from Advicciene, Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, GSK, BoehringerIngelheim, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Sysmex, Novo-Nordisk, and Vifor Fresenius Medical Care Renal Pharma; and is board member of ERA council and SOMANE. K.J.J. reports receiving funds from European Renal Association and European Society for Paediatric Nephrology, and is board member of SHARE RR working group. V.S.S. reports having support for the present manuscript from European Renal Association. All other co-authors declare that they have no relevant financial interests.